Rigel Pharmaceuticals | RIGL - Current Liabilities

Stock Price
30.29
Daily Change
-0.43 -1.40%
Monthly
15.21%
Yearly
57.11%
Q2 Forecast
29.64

Rigel Pharmaceuticals reported $94.4M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agenus USD 323.49M 36.36M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Anika Therapeutics USD 21.91M 2.82M Dec/2025
Arrowhead Research USD 347.42M 151.94M Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Celldex Therapeutics USD 50.99M 4.53M Dec/2025
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Intrexon USD 23.02M 38K Jun/2024
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Ligand Pharmaceuticals USD 37.45M 6.91M Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Veracyte USD 59.94M 12.22M Dec/2025